Table 5.
Disease response and PET SUV change relative to baseline after single dose of intratumoral HSV1716 in non-injected target lesions.
| Patient | Localized or Distant Mets | Day 14 CT/MRI | Day 14 PET | Day 28 CT/MRI | Day 28 PET |
|---|---|---|---|---|---|
| HSV01 | N/A | N/A | N/A | ND | ND |
| HSV02 | Distant (brain) | N/A | N/A | PD | Not measured |
| HSV03 | N/A | N/A | N/A | N/A | N/A |
| HSV04 | Local (T3/4 paraspinal mass) | PD (10.5 to 14.5 cm) | SUV ↑ (22.5 to 24.6) | ND | ND |
| HSV05-A | Clival recurrence (local) | SD (3.9 to 3.8 cm) | SUV stable (3.9 to 4) | PD (4.7 cm) | ND |
| HSV05-B | Mets posterior to cerebellum (local) | SD (1.3 to 1.5 cm) | Not measured | SD (1.4 cm) | ND |
| HSV07 | Subcarinal node (distant) | SD (2.9 to 3.2 cm) | SUV stable (4.3 to 4.5) | SD (3.4 cm) | ND |
| HSV08-A | Left anterior perihilar metastatic lesion (distant) | PD (1.9 to 3 cm) | SUV ↑↑ (2.5 to 6.6) | PD (5.7 cm) | SUV stable (2.5) |
| HSV08-B | Metastatic lesion in left upper lobe of lung (distant) | PD (1 to 2.5 cm) | SUV ↑ (1.2 to 2.8) | PD (4.2 cm) | SUV ↑ (3.1) |
| HSV09-A | Pretracheal lymph node (distant) | SD | SUV stable (4.1 to 4.2) | SD | SUV stable (4.1) |
N/A = not applicable; ND = not done; PD = progressive disease; SD = stable disease; SUV = standardized uptake value; cm = centimeters. Letters A and B indicate different measurable but uninjected lesions in the same patient.